comparing the benefit of tablet PREGABALIN with tablet DULOXETINE and only tablet PREGABALIN in nerve pain in diabetes and relation with PPARG and Akt gene
- Conditions
- Health Condition 1: E134- Other specified diabetes mellituswith neurological complications
- Registration Number
- CTRI/2021/02/031068
- Lead Sponsor
- IVERSITY COLLEGE OF MEDICAL SCIENCES
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Male or female patientsâ?? >= 18 years of age with pain due to diabetic peripheral neuropathy
caused by type -I or II Diabetes mellitus for at least 3 months with confirmed diagnosis
on Michigan Neuropathy Screening instrument with score >=3 at the time of screening.
2.Patients must have average pain severity of >= 4/10 on NRS.
3. Brief Pain Inventory- Modified short form (BPI- MSF) >= 4.
4.Patients should have stable glycemic control with HbA1C < 12%.
1.Patients who had received duloxetine or pregabalin in the past except for less than 15
days course.
2. Evidence of other sources of pain that may confound the diagnosis or recent history of
surgery.
3.Patients with past history of MI, liver disease, pancreatitis and vasculitis, heart failure,
seizure, & arrhythmia.
4. Patients with evidence of renal impairment, diabetic foot ulcer/gangrene of the foot &
history of alcohol consumption and smoking.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method